News and Trends 18 Nov 2022 Novavax’ COVID-19 vaccine gets expanded authorization for booster in adults Novavax, Inc., a U.S-based biotechnology company announced today (November 18) that Health Canada has granted expanded authorization for Covid-19 vaccine Nuvaxovid. The vaccine NVX-CoV2373 for active immunization to prevent the disease caused by severe acute respiratory syndrome (SARS-CoV-2) as a homologous booster in adults aged 18 and older. “Canadians now have access to our […] November 18, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
More News! 18 Nov 2022 Triastek cleared for 3D printed medicine treatment of ulcerative colitis Triastek, Inc. has received clearance for its Investigational New Drug (IND) application from the United States Food and Drug Administration (FDA) to initiate clinical studies of the 3D printed medicine, T21, a potential treatment for ulcerative colitis. “We are excited to receive IND clearance to begin clinical trials of this potentially transformative treatment for patients,” […] November 18, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 18 Nov 2022 Sanofi’s Enjaymo for hemolytic anemia given marketing authorization by EC Sanofi’s treatment, Enjaymo, for hemolytic anemia in adult patients with cold agglutinin disease (CAD), has been granted marketing authorization by the European Commission (EC). Enjaymo is the first and only approved therapeutic option for the rare, serious and chronic autoimmune disease where the body mistakenly attacks healthy red blood cells and causes their rupture, known […] November 18, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 18 Nov 2022 MIF invests in KAHR to explore lead immunotherapy drug for multiple myeloma KAHR Medical, a clinical stage biotech company that is developing a treatment for solid tumors and blood cancers has received investment from the Myeloma Investment Fund (MIF). MIF has made the investment to explore the potential of DSP107, KAHR’s leading immunotherapy drug candidate for the treatment of multiple myeloma. “We are thrilled to partner with […] November 18, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 18 Nov 2022 NW Bio reports positive top-line results from phase 3 glioblastoma trial Northwest Biotherapeutics, which is developing DCVax personalized immune therapies for solid tumor cancers, yesterday (November 17) reported that both median and long tail survival were increased in both newly diagnosed and recurrent glioblastoma. The brain tumor cancer patients were treated with DCVax-L and in its phase 3 clinical trial met both the primary and secondary […] November 18, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 18 Nov 2022 New discovery gives hope in fight against metastatic cancer Cancer that splits and develops in new organs around the body becomes significantly more difficult to fight. Researchers at Chalmers University of Technology, Sweden, have shown that these metastatic cancers, which spread from the original, adapt their metabolism to the tissue in which they grow. The discovery represents a breakthrough for the understanding of metastatic […] November 18, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Interview 18 Nov 2022 How cardioids can usher in the next generation of drug discovery The California-based Molecular Devices brings automated 3D cell culture and image analysis together with HeartBeat.bio’s cardioid technology to enable unique and scalable drug discovery and cardiac safety testing. Cardiovascular diseases are the leading cause of death worldwide, claiming an estimated 17.9 million lives each year. Despite this, the cardiovascular therapeutics market has lagged behind the […] November 18, 2022 - 6 minutesmins - By Omnia Ibrahim Share WhatsApp Twitter Linkedin Email
News and Trends 18 Nov 2022Beyond Biotech podcast 23: World Antimicrobial Awareness Week, PsychoGenics This week, we have three interviews on the theme of antimicrobial resistance (AMR), to mark World Antimicrobial Awareness Week. We spoke with Holger Zimmermann, CEO of anti-infectives company AiCuris; Neil Clark, CEO of Destiny Pharma, and Fredrik Almqvist, co-founder of QureTech Bio. We also have an interview with the chief scientific officer at PsychoGenics, Mark Varney. […] November 18, 2022 Share WhatsApp Twitter Linkedin Email
News and Trends 18 Nov 2022 AstraZeneca and Daiichi Sankyo’s Enhertu recommended for approval AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) for patients previously treated HER-2 positive advanced gastric cancer. The drug is also used for gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen. Enhertu is a specifically engineered HER2-directed antibody drug conjugate (ADC) being jointly developed and commercialized by AstraZeneca […] November 18, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
Best in Biotech 17 Nov 2022 The hottest private biotech companies in Canada Canada is well known for biotech innovations, with expertise in genomics, cell therapies and liquid biopsy. Here is a list of private healthcare biotech companies that have attracted big cash in Canada in the past two years. Canada has one of the top 10 biggest economies in the world. The developed country boasts rich forests, […] November 17, 2022 - 6 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 17 Nov 2022 Ascletis announces IND approval for treatment of advanced solid tumors Ascletis Pharma has announced the approval of the investigational new drug (IND) application by China National Medical Products Administration (NMPA). The approval is for an in-house developed oral PD-L1 small molecule inhibitor prodrug, ASC61, for the treatment of advanced solid tumors. The ASC61 phase 1 dose escalation study is ongoing in the U.S. IND approval […] November 17, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 17 Nov 2022 New EU project looks to unlock the potential of genomics The European Genomic Data Infrastructure (GDI) project kicked off today in Brussels, Belgium. The new €40 million ($41.4 million) GDI project, coordinated by ELIXIR, is jointly funded by the European Commission under the Digital Europe Programme and through co-funding from participating Member States. In the area of health, the Digital Europe Programme aims to support […] November 17, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email